JAK2 Inhibitors for Myeloproliferative Neoplasms: What Is Next?

Although JAK2 inhibitors provide substantial clinical benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are under study, particularly in myelofibrosis and essential thrombocythemia.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.